在芳香化酶抑制剂联合哌柏西利治疗期间出现ESR1突变升高的晚期乳腺癌中切换至氟维司群联合哌柏西利对比不切换(PADA-1):一项随机、开放标签、多中心、3期试验
PADA-1研究在法国83家医院入组1017例激素受体阳性、HER2阴性晚期乳腺癌患者,在一线芳香化酶抑制剂联合哌柏西利治疗中监测血ESR1突变升高。279例出现ESR1突变升高且无同步疾病进展者中172例随机分配至切换氟维司群联合哌柏西利组或继续原方案组,切换组中位无进展生存期11.9个月对比5.7个月(分层HR 0.61,95%CI 0.43-0.86;p=0.0040)。
要点
- 一线芳香化酶抑制剂联合哌柏西利治疗中血ESR1突变升高且无疾病进展者,早期切换至氟维司群联合哌柏西利可显著改善无进展生存期。
- 切换组中位无进展生存期11.9个月对比继续组5.7个月,分层HR 0.61(95%CI 0.43-0.86;p=0.0040)。
- 3级及以上血液学不良事件最常见为中性粒细胞减少(715/1017,70.3%)、淋巴细胞减少(66/1017,6.5%)和血小板减少(20/1017,2.0%)。
核心结论
- PADA-1是首个前瞻性随机试验,显示对血ESR1突变升高进行早期治疗靶向可带来显著临床获益。
- PADA-1的原创设计可能有助于未来试验中用新药应对获得性耐药。
研究设计与样本
- 随机、开放标签、多中心、3期试验,在法国83家医院开展。
- 入组年龄≥18岁、雌激素受体阳性、HER2阴性晚期乳腺癌且ECOG体能状态0-2分的女性,在一线芳香化酶抑制剂(来曲唑2.5 mg、阿那曲唑1 mg或依西美坦25 mg,口服每日一次持续服用)联合哌柏西利(125 mg口服,每28天周期第1-21天每日一次)治疗期间监测血ESR1突变升高。
- 新出现或升高的血ESR1突变且无同步疾病进展者按1:1随机分配至继续原方案或切换至氟维司群(500 mg肌内注射,每28天周期第1天及第1周期第15天)联合哌柏西利(剂量不变)。
- 随机化序列由交互式网络应答系统采用最小化法(80%随机因素)生成,按内脏受累(有或无)和自入组至检测到ESR1突变的时间(<12个月或≥12个月)分层。
- 共同主要终点为意向治疗人群(即所有随机分配患者)中研究者评估的从随机分配起的无进展生存期,以及所有患者中3级或以上血液学不良事件。
主要发现
- 2017年3月22日至2019年1月31日共入组1017例患者,其中279例(27%)出现血ESR1突变升高,172例(17%)随机分配治疗:88例切换至氟维司群联合哌柏西利,84例继续芳香化酶抑制剂联合哌柏西利。
- 数据锁库日期2021年7月31日,随机分配患者自入组中位随访35.3个月(IQR 29.2-41.4),自随机分配中位随访26.0个月(IQR 13.8-34.3)。
- 从随机分配起中位无进展生存期:氟维司群联合哌柏西利组11.9个月(95%CI 9.1-13.6)对比芳香化酶抑制剂联合哌柏西利组5.7个月(95%CI 3.9-7.5),分层HR 0.61(95%CI 0.43-0.86;p=0.0040)。
- 总体人群中3级或以上血液学不良事件最常见为中性粒细胞减少(715/1017,70.3%)、淋巴细胞减少(66/1017,6.5%)和血小板减少(20/1017,2.0%)。
- 第二步治疗中3级或以上不良事件最常见为中性粒细胞减少(芳香化酶抑制剂联合哌柏西利组35/84,41.7% vs 氟维司群联合哌柏西利组39/88,44.3%)和淋巴细胞减少(3/84,3.6% vs 4/88,4.5%);总体人群中31例(3.1%)发生与治疗相关的3级或以上严重不良事件。
关键数值与推荐
- 共同主要终点无进展生存期在意向治疗人群中分析,从随机分配起计算。
- 分层HR 0.61(95%CI 0.43-0.86;p=0.0040)支持切换至氟维司群联合哌柏西利。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which might be sensitive to fulvestrant. The PADA-1 trial aimed to show the efficacy of an early change in therapy on the basis of a rising ESR1 mutation in blood (bESR1mut), while assessing the global safety of combination fulvestrant and palbociclib. METHODS: We did a randomised, open-label, phase 3 trial in 83 hospitals in France. Women aged at least 18 years with oestrogen receptor-positive, HER2-negative advanced breast cancer and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited and monitored for rising bESR1mut during first-line aromatase inhibitor (2·5 mg letrozole, 1 mg anastrozole, or 25 mg exemestane, orally once per day, taken continuously) and palbociclib (125 mg orally once per day on days 1-21 of a 28-day cycle) therapy. Patients with newly present or increased bESR1mut in circulating tumour DNA and no synchronous disease progression were randomly assigned (1:1) to continue with the same therapy or to switch to fulvestrant (500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1) and palbociclib (dosing unchanged). The randomisation sequence was generated within an interactive web response system using a minimisation method (with an 80% random factor); patients were stratified according to visceral involvement (present or absent) and the time from inclusion to bESR1mut detection (<12 months or ≥12 months). The co-primary endpoints were investigator-assessed progression-free survival from random assignment, analysed in the intention-to-treat population (ie, all randomly assigned patients), and grade 3 or worse haematological adverse events in all patients. The trial is registered with Clinicaltrials.gov (NCT03079011), and is now complete. FINDINGS: From March 22, 2017, to Jan 31, 2019, 1017 patients were included, of whom 279 (27%) developed a rising bESR1mut and 172 (17%) were randomly assigned to treatment: 88 to switching to fulvestrant and palbociclib and 84 patients to continuing aromatase inhibitor and palbociclib. At database lock on July 31, 2021, randomly assigned patients had a median follow-up of 35·3 months (IQR 29·2-41·4) from inclusion and 26·0 months (13·8-34·3) from random assignment. Median progression-free survival from random assignment was 11·9 months (95% CI 9·1-13·6) in the fulvestrant and palbociclib group versus 5·7 months (3·9-7·5) in the aromatase inhibitor and palbociclib group (stratified HR 0·61, 0·43-0·86; p=0·0040). The most frequent grade 3 or worse haematological adverse events were neutropenia (715 [70·3%] of 1017 patients), lymphopenia (66 [6·5%]), and thrombocytopenia (20 [2·0%]). The most common grade 3 or worse adverse events in step 2 were neutropenia (35 [41·7%] of 84 patients in the aromatase inhibitor and palbociclib group vs 39 [44·3%] of 88 patients in the fulvestrant and palbociclib group) and lymphopenia (three [3·6%] vs four [4·5%]). 31 (3·1%) patients had grade 3 or worse serious adverse events related to treatment in the overall population. Three (1·7%) of 172 patients randomly assigned had one serious adverse event in step 2: one (1·2%) grade 4 neutropenia and one (1·2%) grade 3 fatigue among 84 patients in the aromatase inhibitor and palbociclib group, and one (1·1%) grade 4 neutropenia among 88 patients in the fulvestrant and palbociclib group. One death by pulmonary embolism in step 1 was declared as being treatment related. INTERPRETATION: PADA-1 is the first prospective randomised trial showing that the early therapeutic targeting of bESR1mut results in significant clinical benefit. Additionally, the original design explored in PADA-1 might help with tackling acquired resistance with new drugs in future trials. FUNDING: Pfizer.
引用
- Bidard FC, Hardy-Bessard AC, Dalenc F, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022. PMID: 36183733. doi:10.1016/S1470-2045(22)00555-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。